Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial (Annals of the Rheumatic Diseases, 2019)

(untitled) - Sweet, K; Dasgupta, B; De Vries, D; Gourley, I; Hsu, B; Loza, M; Taylor, P